Turkovac

Turkovac^[2] (pronunciation: ['tɜ:rkəvæk]) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.

Turkovac

Vaccine description
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Other names	Erucov-Vac
Routes of administration	Intramuscular
Legal status
Legal status	Full list of Turkovac authorizations
Identifiers
CAS Number	2695585-27-2[1]

Clinical trials

In November 2020, Turkovac started on phase I trials with 44 participants in Turkey.^[3]

In February 2021, Turkovac started on phase II trials with 250 participants in Turkey.^[4]

In June 2021, Turkovac started on phase III trials with 40,800 participants in Turkey.^[5] As of 2023^[update] phase III trials continue.^[6]

Authorization

On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed.^[7] On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.^[8]